Coupon Accepted Successfully!


New Drugs

  1. Dapoxetine,
    1. It is the first compound developed specially for the treatment of premature ejaculation(PE) in men 18–24 years old.
    2. Dapoxetine works by inhibiting serotonin transporter, increasing serotonin’s action at the post synaptic cleft, and as a consequence promoting ejaculatory delay.
    3. As a member of selective serotonin reuptake inhibitor (SSRI) family, dapoxetine was initially created as an antidepressant.
    4. However, unlike other SSRIs, dapoxetine is absorbed and eliminated rapidly in the body.
    5. Its fast acting property makes it suitable for the treatment of PE but not as an antidepressant
Mechanism of actions
  1. Dapoxetine acts by inhibiting serotonin transporter and subsequently increasing serotonin’s action at pre and postsynaptic receptors.
Adverse effects
The most common effects when taking dapoxetine are nausea, dizziness, dry mouth, headache, diarrhea, and insomnia. Discontinuation due to adverse effects is dose related.
  1. Agomelatine
    1. It is an antidepressant drug for the treatment of major depressive disorder and has been reported to have a reduced level of sexual side effects as well as discontinuation effects compared to some other antidepressants.
    2. Agomelatine may also have positive effects on sleep.
    3. Agomelatine is a melatonergic agonist MT1 and MT2 receptors and 5-HT2C antagonist.
    4. Binding studies indicate that it has no effect on monoamine uptake and no affinity for adrenergic, histaminergic, cholinergic, dopaminergic and benzodiazepine receptors, nor other serotonergic receptors.
  1. Agomelatine resynchronises circadian rhythms in animal models of delayed sleep phase syndrome and other circadian rhythm disruptions.
  2. It increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin.
Side Effects
  1. No relevant modification in agomelatine pharmacokinetic parameters in patients with severe renal impairment has been observed.
  2. Agomelatine is contraindicated in patients with hepatic impairment.
  1. Milnacipram :
    1. It is a newer anti depressant.
    2. It is nor adrenergic blocker as well as serotonin blocker.
    3. It has more blocking activity for nor adrenergic receptors thereby has better efficacy in retarded depression.
  2. Magnesium valproate (MgVPA)
    1. It is an anticonvulsant, and the effects it exerts are the result of valproic acid and magnesium acting in a complementary way.
    2. The effects of valproic acid alone are well documented; it is thought to increase the cerebral concentration of -aminobutyric acid (GABA), increase the Cl - and K + ion conductance, and reduce N-methyl-D-aspartate (NMDA) receptor stimulation. 

Test Your Skills Now!
Take a Quiz now
Reviewer Name